Ειδήσεις: PHASE_III | PXAI

10/04 08:02 defenseworld.net

Mesoblast R&D Day: Ryonsel Gains Traction, Back Pain Phase III Nears Finish, New Shots on Goal

Mesoblast Ryonsel Phase III rexlemestrocel MSC therapy R&D Day

02/04 11:26 defenseworld.net

Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial

Oric Pharmaceuticals rinzimetostat PRC2 inhibitor metastatic castration‑resistant prostate cancer phase III Himalayas‑1

24/03 18:19 defenseworld.net

VistaGen Therapeutics Highlights Fasedienol PALISADE-4 Readout Timing, AI Tools to Tackle Placebo Effect

VistaGen fasedienol PALISADE Phase III social anxiety Fast Track

18/03 07:06 defenseworld.net

4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference

4D Molecular Therapeutics 4D‑150 Phase III wet AMD DME gene therapy

17/03 09:06 defenseworld.net

Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference

Edgewise Therapeutics Becker muscular dystrophy Phase III cardiovascular ejection fraction NT‑proBNP

16/03 09:02 defenseworld.net

Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum

Cadrenal Therapeutics CAD‑1005 HIT Phase III heparin‑induced thrombocytopenia in‑licensing

16/03 09:02 defenseworld.net

Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum

Cadrenal Therapeutics CAD‑1005 HIT Phase III heparin‑induced thrombocytopenia in‑licensing

Loading...